Oluwatosin Abideen Saibu

Oluwatosin Abideen Saibu

Auto-generated profile, based on publicly available information

Oluwatosin Abideen Saibu

Department of Environmental Toxicology, Universitat Duisburg-Essen, NorthRhine-Westphalia, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
TBToheeb Balogun
Toheeb Balogun
MIMuhammad Nasir Iqbal
Muhammad Nasir Iqbal
OSOluwatosin Abideen Saibu
Oluwatosin Abideen Saibu
MAMichael Olawale Akintubosun
Michael Olawale Akintubosun
OLOlubodun Michael Lateef
Olubodun Michael Lateef
DODamilola Omoboyowa
Damilola Omoboyowa
Human epidermal growth factor receptor 2 (HER2) is a member of epidermal growth factor receptors with tyrosine kinase functionality. The dimerization of HER2 leads to the autophosphorylation of tyrosine residues within its cytoplasmic domain, resulting in hyperactivation of several downstream signal transduction pathways that play an important role in tumorigenesis, cancer aggressiveness and cell proliferation. Amplification or overexpression of HER2 has been found in approximately 15–30% of breast cancers. Hence, HER2 serve as a therapeutic biomarker in breast cancer. Herein, we applied structural bioinformatics techniques via molecular docking, molecular dynamics simulations, Molecular mechanics/generalized Born surface area (MM/GBSA) calculations and pharmacokinetic models to identify putative HER2 inhibitors. Application of stringent molecular docking results in the identification of bioactive compounds from Mangifera indica as selective, potent inhibitors of HER2. However, only the top three compounds with the highest negative docking score (< −9kcal/mol) was considered in reference to neratinib (−8.601 kcal/mol) for computational analysis. The molecular dynamics simulations and post-simulation analysis of docked HER2-ligand complexes unveil the substantial stability for M. indica ligands over the 100 ns simulation period. Additionally, MM/GBSA binding free energy calculation supports the inhibitory potential for the docked ligands, which exclusively revealed the highest binding energy for selected M. indica ligands than the reference compound (neratinib). The pharmacokinetic model showed that M. indica ligands are promising therapeutic agents. Conclusively, bioactive compounds from M. indica may serve as lead molecules that could be developed into potent and effective HER2 inhibitors for breast cancer treatment. Communicated by Ramaswamy H. Sarma

25 December 2021 in Biology Methods and Protocols
Verified
Journal Article
Open access
PDF file
DODamilola Omoboyowa
Damilola Omoboyowa
TBToheeb Balogun
Toheeb Balogun
OSOluwatosin A Saibu
Oluwatosin A Saibu
ODOnyeka S. san diego
Onyeka S. san diego
AAAbdullahi Alausa
Abdullahi Alausa
SMSekinat O Musa
Sekinat O Musa
Prostate cancer (PCa) is the most common malignancy found in men and the second leading cause of cancer-related death worldwide. Castration-resistant PCa (CRPC) is defined by PCa cells that stop responding to hormone therapy. Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) plays a critical role in the biosynthesis of androgens in humans. Androgen signaling cascade is a principal survival pathway for PCa cells and androgen-deprivation therapy (ADT) remains the key treatment for patients marked with locally advanced and metastatic PCa cells. Available synthetic drugs have been reported for toxicity, drug resistance, and decreasing efficacy. Thus, the design of novel selective inhibitors of CYP17A1 lyase would help circumvent associated side effects and improve pharmacological activities. Therefore, we employed structural bioinformatics techniques via molecular docking; molecular mechanics generalized born surface area (MM-GBSA), molecular dynamics (MD) simulation, and pharmacokinetic study to identify putative CYP17A1 lyase inhibitors. The results of the computational investigation showed that the Prunus dulcis compounds exhibited higher binding energy than the clinically approved abiraterone acetate. The stability of the ligand with the highest binding affinity (quercetin-3-o-rutinoside) was observed during MD simulation for 10 ns. Quercetin-3-o-rutinoside was observed to be stable within the active site of CYP17A1Lyase throughout the simulation period. The result of the pharmacokinetic study revealed that these compounds are promising therapeutic agents. Collectively, this study proposed that bioactive compounds from P. dulcis may be potential selective inhibitors of CYP17A1Lyase in CRPC treatments.

8 February 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
OSOluwatosin A. Saibu
Oluwatosin A. Saibu
GSGagandeep Singh
Gagandeep Singh
SOSunday A. Olugbodi
Sunday A. Olugbodi
AOAdenrele T. Oluwafemi
Adenrele T. Oluwafemi
TATemitope M. Ajayi
Temitope M. Ajayi
DODamilola Omoboyowa
Damilola Omoboyowa
Breast cancer remains a major world health challenge in women. Some Breast cancers are human epidermal growth factor receptor 2 (HER2) positive. Since this protein promotes the growth of cancer cells, it remains a therapeutic target for novel drugs. This study uses in silico model to predict HER2 inhibitors from curcumin derivatives via QSAR, e-pharmacophore, ADMET as well as structure-based virtual screening using Schrodinger suite. The molecular dynamics simulation of lead compounds, reference ligand and co-crystalized ligand was performed using GROMACS. At the end, eight active curcumin derivatives were predicted as inhibitors of HER2 with high binding affinity and better interaction compared with the reference drug (Neratinib) but lower binding affinity compared with the co-crystalized ligand (TAK-285). After prediction of the bioactivity of the molecules using AutoQSAR, the hit compounds showed appreciable inhibitory pIC50 compared with the reference and co-crystalized ligands against HER2. The pharmacokinetics profile predicted the eight hit compounds as drug-like and drug candidates. The MD simulation predicted the stability of the two top-scored compounds (10763284 and 78321412) in complex with HER2 for the final 80 ns of the trajectory period after initial equilibration with higher H-bond interactions in the protein-reference drug complex compared to the hit compounds-HER2 complexes. This study revealed that curcumin derivatives especially (1E,6E)-1,8-bis(4-hydroxy-3-methoxyphenyl)octa-1,6-diene-3,5-dione and (1E,6E)-4-ethyl-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione were identified to demonstrate inhibitory activity against HER2 which is comparable to neratinib. Conclusively, the lead compounds require further in vitro and in vivo experimental validation for the discovery of new HER2 antagonists for breast cancer management. Communicated by Ramaswamy H. Sarma

29 January 2023 in Journal of Taibah University Medical Sciences
Verified
Journal Article
Open access
DODamilola Omoboyowa
Damilola Omoboyowa
MAMary D. Agoi
Mary D. Agoi
SSSidiqat A. Shodehinde
Sidiqat A. Shodehinde
OSOluwatosin A. Saibu
Oluwatosin A. Saibu
JSJamiyu A. Saliu
Jamiyu A. Saliu
The onset of insulin resistant diabetes has been associated with a high-sucrose diet in vertebrates and invertebrates. However, various parts of Spondias mombin reportedly possess antidiabetic potential. However, the antidiabetic efficacy of S. mombin stem bark in high-sucrose diet-induced Drosophila melanogaster model has not been explored. In this study, the antidiabetic and antioxidant effects of the solvent fractions of S. mombin stem bark were evaluated using in vitro, in vivo, and in silico methods. Successive fractionation of S. mombin stem bark ethanol extract was performed; the resulting fractions were subjected to in vitro antioxidant and antidiabetic assays using standard protocols. The active compounds identified from the high-performance liquid chromatography (HPLC) study of the n-butanol fraction were docked against the active site of Drosophila α-amylase using AutoDoc Vina. The n-butanol and ethyl acetate fractions of the plant were incorporated into the diet of diabetic and nondiabetic flies to study the in vivo antidiabetic and antioxidant properties. The results obtained revealed that n-butanol and ethyl acetate fractions had the highest in vitro anti-oxidant capacity by inhibiting 2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing antioxidant power, and hydroxyl radical followed by significant inhibition of α-amylase. HPLC analysis revealed the identification of eight compounds with quercetin having the highest peak followed by rutin, rhamnetin, chlorogenic acid, zeinoxanthin, lutin, isoquercetin, and rutinose showing the lowest peak. The fractions restored the glucose and antioxidant imbalance in diabetic flies, which is comparable with the standard drug (metformin). The fractions were also able to upregulate the mRNA expression of insulin-like peptide 2, insulin receptor, and ecdysone-inducible gene 2 in diabetic flies. The in silico studies revealed the inhibitory potential of active compounds against α-amylase with isoquercetin, rhamnetin, rutin, quercetin, and chlorogenic acid having higher binding affinity than the standard drug (acarbose). Overall, the butanol and ethyl acetate fractions of S. mombin stem bark ameliorate type 2 diabetes in Drosophila. However, further studies are needed in other animal models to confirm the antidiabetes effect of the plant.

1 August 2020 in International Journal of Biochemistry Research & Review
Verified
Journal Article
Open access
PDF file
TBToheeb Balogun
Toheeb Balogun
DODamilola Omoboyowa
Damilola Omoboyowa
OSOluwatosin A. Saibu
Oluwatosin A. Saibu
Chemotherapy remains the kernel of malaria control and the available antimalarial drugs are not only expensive but also parade heterogeneous levels of toxicity and may invoke poor compliance in patients. The present study focuses on the screening of quinolone compounds against Plasmodium falciparum dihydrofolate reductase (pfDHFR) for anti-malarial potential using Glide (Schrodinger maestro 2017-1). Computational tool using Glide was employed to investigate the therapeutic relevance of six (6) quinolone derivatives retrieved from PUBCHEM via molecular docking against pfDHFR retrieved from protein data base. The results showed that, Lascufloxacin and moxifloxacin bind with higher affinity and lower free energy with catalytic domain of pfDHFR with glide score of -6.597 and -5.653 respectively compared to standard ligand (quinine) with glide score of -3.728. Lascufloxacin interacted with amino acid residue of the catalytic domain (SER 511, ARG 510, GLU 382) as evaluated by energy decomposition per residue lascufloxacin-pfDHFRcomplex. The results from this investigation, thus proposed quinolone derivatives as hit lead drug candidates which may be consider as potential inhibitor of pfDHFR.

18 November 2023 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
TOTope T. Odunitan
Tope T. Odunitan
OSOluwatosin A. Saibu
Oluwatosin A. Saibu
BABoluwatife T. Apanisile
Boluwatife T. Apanisile
DODamilola A. Omoboyowa
Damilola A. Omoboyowa
TBToheeb A. Balogun
Toheeb A. Balogun
WAWaliu O. Abdulazeez
Waliu O. Abdulazeez